IDH mutation, glioma immunogenicity, and therapeutic challenge of primary mismatch repair deficient IDH ‐mutant astrocytoma PMMRDIA : a systematic review
Molecular Oncology · 2024-12 · 18 (12) · 2822-2841
DOI: 10.1002/1878-0261.13598 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Molecular Oncology, online erschienen am 09.02.2024. Verfasst von Olfat Ahmad und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Neurooncology, Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Astrocytoma, Mutation, Brain Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In 2021, Suwala et al. described Primary Mismatch Repair Deficient IDH‐mutant Astrocytoma (PMMRDIA) as a distinct group of gliomas. In unsupervised clustering, PMMRDIA forms distinct cluster, separate from other IDH‐mutant gliomas, including IDH‐mutant gliomas with secondary mismatch repair (MMR) deficiency. In the published cohort, three patients received treatment with an immune checkpoint blocker (ICB), yet none exhibited a response, which aligns with existing knowledge about the decreased immunogenicity of IDH‐mutant gliomas in comparison to IDH‐wildtype. In the case of PMMRDIA, the inherent resistance to the standard‐of‐care temozolomide caused by MMR deficiency is an additional challenge. It is known that a gain‐of‐function mutation of IDH1/2 genes produces the oncometabolite R‐2‐hydroxyglutarate (R‐2‐HG), which increases DNA and histone methylation contributing to the characteristic glioma‐associated CpG island methylator phenotype (G‐CIMP). While other factors could be involved in remodeling the tumor microenvironment (TME) of IDH‐mutant gliomas, this systematic review emphasizes the role of R‐2‐HG and the subsequent G‐CIMP in immune suppression. This highlights a potential actionable pathway to enhance the response of ICB, which might be relevant for addressing the unmet therapeutic challenge of PMMRDIA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Neurooncology, Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany.
- Institute of Human Genetics, University Hospital Heidelberg, Heidelberg, Germany.
- University of Oxford, Oxford, UK.
- King Hussein Cancer Center (KHCC), Amman, Jordan.
- Department of Pediatric Neuroradiology, IWK Health Center, Halifax, Canada.
ORCID-Profile: Olfat Ahmad
Zitieren
APA
Ahmad, O., Ahmad, T., & Pfister, S. M. (2024). IDH mutation, glioma immunogenicity, and therapeutic challenge of primary mismatch repair deficient IDH ‐mutant astrocytoma PMMRDIA : a systematic review. Molecular Oncology, 18(12), 2822-2841. https://doi.org/10.1002/1878-0261.13598
Vancouver
Ahmad O, Ahmad T, Pfister SM. IDH mutation, glioma immunogenicity, and therapeutic challenge of primary mismatch repair deficient IDH ‐mutant astrocytoma PMMRDIA : a systematic review. Molecular Oncology. 2024;18(12):2822-2841. doi:10.1002/1878-0261.13598
BibTeX
@article{Ahmad2024,
author = {Ahmad, Olfat and Ahmad, Tahani and Pfister, Stefan M},
title = {IDH mutation, glioma immunogenicity, and therapeutic challenge of primary mismatch repair deficient IDH ‐mutant astrocytoma PMMRDIA : a systematic review},
journal = {Molecular Oncology},
year = {2024},
volume = {18},
number = {12},
pages = {2822--2841},
doi = {10.1002/1878-0261.13598}
}
EUVIMED